| Autor: |
Coopmans EC; Department of Internal Medicine, Endocrinology Section, Pituitary Center Rotterdam, Erasmus University Medical Center, Rotterdam, the Netherlands., van Meyel SWF; Department of Internal Medicine, Endocrinology Section, Pituitary Center Rotterdam, Erasmus University Medical Center, Rotterdam, the Netherlands., Pieterman KJ; Departments of Radiology and Medical Informatics, Biomedical Imaging Group Rotterdam., van Ipenburg JA; Department of Pathology, Erasmus University Medical Center, Rotterdam, the Netherlands., Hofland LJ; Department of Internal Medicine, Endocrinology Section, Pituitary Center Rotterdam, Erasmus University Medical Center, Rotterdam, the Netherlands., Donga E; Department of Internal Medicine, Endocrinology Section, Elisabeth TweeSteden Hospital, Tilburg, the Netherlands., Daly AF; Department of Endocrinology, University of Liège, Liège, Belgium., Beckers A; Department of Endocrinology, University of Liège, Liège, Belgium., van der Lely AJ; Department of Internal Medicine, Endocrinology Section, Pituitary Center Rotterdam, Erasmus University Medical Center, Rotterdam, the Netherlands., Neggers SJCMM; Department of Internal Medicine, Endocrinology Section, Pituitary Center Rotterdam, Erasmus University Medical Center, Rotterdam, the Netherlands. |
| Abstrakt: |
Prolactinomas are the most commonly encountered pituitary adenomas in the clinical setting. While most can be controlled by dopamine agonists, a subset of prolactinomas are dopamine-resistant and very aggressive. In such tumors, the treatment of choice is neurosurgery and radiotherapy, with or without temozolomide. Here, we report a patient with an highly aggressive, dopamine-resistant prolactinoma, who only achieved biochemical and tumor control during pasireotide long-acting release (PAS-LAR) therapy, a second-generation somatostatin receptor ligand (SRL). Interestingly, cystic degeneration, tumor cell necrosis or both was observed after PAS-LAR administration suggesting an antitumor effect. This case shows that PAS-LAR therapy holds clinical potential in selective aggressive, dopamine-resistant prolactinomas that express somatostatin (SST) receptor subtype 5 and appears to be a potential new treatment option before starting temozolomide. In addition, PAS-LAR therapy may induce cystic degeneration, tumor cell necrosis or both in prolactinomas. |
